News
Canada approves Jivi for hemophilia A
Health Canada has approved Jivi® (antihemophilic factor [recombinant, B-domain deleted, PEGylated]) for use in patients with hemophilia A. Jivi (...
News
‘Mechanoprimed’ MSCs aid hematopoietic recovery
Specially grown mesenchymal stromal cells (MSCs) can improve hematopoietic recovery, according to preclinical research published in Stem Cell...
News
Three gene types drive MM disparity in African Americans
Researchers say they may have determined why African Americans have a two- to three-fold increased risk of multiple myeloma (MM) compared to...
News
MDM2 inhibitors could treat resistant AML
Preclinical research has revealed a potential treatment for chemotherapy-resistant acute myeloid leukemia (AML). Researchers characterized a...
News
Engineered MSCs could treat GVHD
LAUSANNE, SWITZERLAND—A mesenchymal stem cell (MSC) product could treat acute graft-versus-host disease (GVHD), according to preclinical research...
News
Inhibitor could improve HSC donation and transplant
Preclinical research suggests a small-molecule inhibitor could potentially improve the donation and transplant of hematopoietic stem cells (HSCs...
News
Better PFS may not mean better HRQOL
Cancer treatments that prolong progression-free survival (PFS) may not improve health-related quality of life (HRQOL), researchers reported in...
News
Age limits restrict AYA participation in relevant trials
MUNICH—Age limits imposed in European countries can prevent adolescents and young adults (AYAs) from enrolling in appropriate clinical trials, a...
News
Inhibitor receives orphan designation for ITP
The U.S.
News
CHMP recommends change for eptacog alfa
The European Medicine’s Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the terms of the marketing...
News
Study supports sequencing in kids with cancer
SAN DIEGO—Comprehensive next-generation sequencing is both feasible and clinically useful in pediatric cancer patients, a new study suggests....
News
‘Intense’ end-of-life care may be common in HSCT recipients
Patients who die within a year of allogeneic hematopoietic stem cell transplant (HSCT) tend to receive “medically intense” end-of-life care, an...
News
Adoptive T-cell therapy treats PML
Adoptive T-cell therapy has proven effective for treating progressive multifocal leukoencephalopathy (PML), according to research published in The...
News
Dataset could reveal better therapies for AML
Researchers have released a dataset detailing the molecular makeup of tumor cells from more than 500 patients with acute myeloid leukemia (AML)....
News
BTK inhibitor shows early promise for WM
NEW YORK—The BTK inhibitor zanubrutinib has demonstrated “robust activity” and “good tolerability” in patients with Waldenström’s...